Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival after BMT and IFN treatment suggests that a trial of IFN (and possibly STI 571) before proceeding to allografting is a viable, and in low risk patients a probably preferable option. Keywords: IFN; STI571; allografting; CML; survival
The key problem with allografting is its high procedureassociated morbidity and mortality. 1 If there was not the aspect of cure, undergoing allografting is worse than Russian roulette. One out of three or four is likely not to survive whereas Russian roulette, in general, is considered to have a risk of one out of six.
What, at present, would be the chance of cure by allografting? Assuming a median age of 47 years, 2 55% of the patients are younger than 50 years. About 30% of these will have a related donor. Fifty percent of the remaining 70% will have an unrelated donor thanks to more than 6.2 million volunteers worldwide. This means that 65% of patients 50 years or younger will have a related or unrelated donor. At a 5-year survival of 70-75% about half of patients under 50 years may be cured by allografting.
On the other hand, progress with drug treatment during the last decade has considerably improved survival in chronic phase CML, and 10-year survival of interferon ␣ (IFN)-treated low risk patients is about 40% in a cohort of 1377 patients started on IFN soon after diagnosis, and that of cytogenetic responders may be as high as 80% (Talpaz, Bologna 2000). 3 If one compares survival after allografting with that after IFN-based therapies at 3, 5 or 10 years after diagnosis, it is clear that IFN treatment is superior at 3 years: about 95% of low risk and about 80% of intermediate and high risk patients are alive whereas after allografting, due to the early procedure-related mortality, only 55-75% are alive. At 5 years the survival times after BMT and IFN treatment are similar. Only after 10 years is a clear superiority of allografting recognizable with 50-65% of transplanted and only 20-40% of IFN-treated patients alive. 1, [4] [5] [6] [7] [8] [9] The data are shown in Table 1 . According to recent data on the tyrosine kinase inhibitor STI571, 10 the results with drug treatment are likely to become even better soon.
Therefore, why not give a trial with IFN first and proceed to transplantation only if the response to drug treatment is unsatisfactory? There are two reasons arguing against this concept. First, delay of transplantation might lower probability of cure because the success rate of transplantation decreases as time elapsed after the diagnosis of CML increases. Data from: Hansen et al, 1 ICSG on CML, 9 Appelbaum et al, 4 van Rhee et al, 5 Hasford et al, 3 German CML Study Group, 1999. observation has been made, however, only in hydroxyureaand busulfan-treated patients and may not be true after pretreatment with IFN or STI571. Although it is not known why the success rate of allografting declines with the duration of CML, it might well be that irreversible changes occur in the bone marrow or in the hematopoetic stem cells which make treatment less successful. It has been suggested, for instance, that the genetic instability 12 associated with the presence of the Philadelphia (Ph)-chromosome favors progression to more malignant genotypes, selection of ever more aggressive karyotypic variants and aneuploidy 13 as observed in blast crisis. It is questionable whether this evolution occurs if the Ph-chromosome is successfully suppressed by IFN or STI571.
Second, IFN pretreatment per se, in addition to the time aspect, may be harmful for subsequent transplantation because of increased transplantation-related early death rates due to graft rejection or graft-versus-host disease (GVHD). Such an IFN effect would appear plausible since it is well known that IFN interferes with the cytokine network and its complex interactions. Disregulation of cytokines by donor T cells is discussed also as a mechanism underlying GVHD.
Five reports involving more than 300 patients could not confirm adverse effects of pretransplant IFN on subsequent allografting, [14] [15] [16] [17] [18] but two reports found a negative impact under certain conditions, eg before transplantation with unrelated or mismatched donors or after pretreatment with IFN of more than 5 or 12 months duration. 19, 20 Since the reports with adverse outcome were not derived from controlled studies or predefined cohorts of patients, they are subject to referral bias. The referral aspect is critical because IFN-treated patients who respond well to IFN are less likely to be referred for transplantation than patients who respond to IFN poorly or not at all. Another source of bias is the nonrandom assignment of primary treatment. The issue was prospectively studied within two randomized studies of the German CML Study Group comparing IFN (±chemotherapy) vs chemotherapy alone which showed that IFN before BMT does not effect outcome adversely, provided it is discontinued at least 90 days before the procedure. 8 In conclusion, there is no firm evidence in the literature against a trial of IFN first and proceeding to transplantation only after the response has proven unsatisfactory. There is evidence to suggest that IFN pretreatment may be beneficial for outcome after transplantation, if IFN is given for a short period 14 or if it is discontinued 3 months before transplantation. 8 The argument for a trial with drug treatment before allografting becomes even stronger in view of the response rates and low toxicity of STI571. On the basis of a recent update 11 31 out of 31 IFN-resistant patients treated with 300 mg (or more) of ST1571 achieved a complete hematologic remission within 1 month, and after at least 5 months treatment, a cytogenetic response was observed in 14 of these 31 patients. Our own experience with more than 50 IFN-resistant patients confirms these observations. Since ST1571 is an enzyme inhibitor and no interactions with cytokines comparable to IFN have been observed, a negative effect on the outcome of allografting appears unlikely. However, in view of the limited experience with this new drug, caution is required and studies have to be awaited. In summary, there are good reasons for a trial of IFN (and perhaps ST1571) before proceeding to allografting for CML. Allografting could be done when the response to drug treatment is unsatisfactory. On the basis of the experience with IFN, drug treatment should be discontinued at least 3 months before transplantation.
Since a trial of IFN (or ST1571) would postpone allografting and its associated early mortality by up to several years, a prolongation of overall survival in CML is expected. With a postponement of allografting by 3 years and under the assumption of an increase of transplant-related mortality within 3 years of about 10%, 1 what gain of overall survival could be anticipated? Assuming a procedure-related mortality of early allografting of 25-45% (mean: 35%) and of CMLrelated mortality under IFN treatment during the first 3 years of 5-25% depending on the risk profile at diagnosis 3 (mean: 15%) (Table 1) , 20% more patients (30% of low risk, 10% of intermediate and high risk patients) would be alive under drug treatment than after allografting at 3 years. The trade-off, consequently, would be an additional 20% (10-30%, respectively) of patients alive at 3 years vs a possible reduction of the expected cure rate by about 10%.
The extent of gained overall survival time by a trial of IFN first would also depend on transplantation risk 21 and observation time. The higher the transplantation risk and the shorter the observation time, the more the gain of survival is visible. The lower the transplantation risk and the longer the observation time, the lower will be the overall gain of survival time.
It can be concluded that a trial of IFN (and possibly ST1571) before proceeding to allografting for CML is a viable, and in low risk patients a probably preferable option. The ultimate decision, however, will depend on the individual preferences of the patients and their doctors.
Note
This topic was discussed at the annual meeting of the IBMTR/ABMTR, Anaheim, 26-29 March 2000 (Scientific Director: M Horowitz) in a plenary discussion (Chairmen: J Goldman, A Bacigalupo). A vote after the discussion showed that at present about 1/3 of a transplant community of about 600 would be in favor of a trial of IFN or ST1571 before proceeding to allografting.
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